Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | -1.24% | 63.15 | 1.0% | $510.50m | |
| AMGN | Amgen, Inc. | -4.02% | 225.59 | 1.3% | $451.51m | |
| BIIB | Biogen, Inc. | -2.14% | 278.14 | 1.4% | $375.15m | |
| ILMN | Illumina, Inc. | -2.27% | 319.58 | 3.5% | $322.74m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -2.07% | 229.06 | 1.9% | $273.01m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -3.17% | 345.28 | 2.6% | $238.76m | |
| EXAS | EXACT Sciences Corp. | -2.83% | 89.57 | 24.0% | $223.37m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -3.02% | 105.27 | 2.0% | $170.84m | |
| A | Agilent Technologies, Inc. | -0.92% | 88.25 | 1.6% | $130.79m | |
| INCY | Incyte Corp. | -1.92% | 76.74 | 2.5% | $127.16m | |
| BMRN | BioMarin Pharmaceutical, Inc. | 0.61% | 86.15 | 4.3% | $108.27m | |
| SRPT | Sarepta Therapeutics, Inc. | -1.14% | 112.39 | 14.6% | $108.00m | |
| SGEN | Seattle Genetics, Inc. | -1.54% | 113.57 | 6.1% | $103.89m | |
| BLUE | bluebird bio, Inc. | -2.74% | 87.26 | 14.2% | $86.40m | |
| DERM | Dermira, Inc. | -0.27% | 18.71 | 3.8% | $83.32m |
Company Profile
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.